Precision Medicine in Type 2 Diabetes: Targeting SGLT2-Inhibitor Treatment for Kidney Protection

Thijs T Jansz[1*], Katherine G Young[1], Rhian Hopkins[1], Andrew P McGovern[1], Beverley M Shields[1], Andrew T Hattersley[1], Angus G Jones[1], Ewan R Pearson[2], Coralie Bingham[1], Richard A Oram[1], John M Dennis[1], on behalf of the MASTERMIND Consortium

[1]University of Exeter Medical School, University of Exeter, Exeter, UK

[2]Division of Diabetes, Endocrinology, and Reproductive Biology, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

ABSTRACT

Background
Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2-inhibitors) for kidney protection in people with type 2 diabetes (T2D) based on a ≥3mg/mmol albuminuria threshold. However, individuals with preserved estimated glomerular filtration rate (eGFR) and normal or low-level albuminuria were not represented in kidney outcome trials, leaving uncertainty about who may have absolute benefit. We therefore developed and validated a model using routine clinical features to predict kidney protection benefit with SGLT2-inhibitors in these individuals.

Methods
We developed a model to predict kidney protection benefit with SGLT2-inhibitors (3-year individual-level absolute risk reductions) by integrating the relative treatment effect from previous trial meta-analysis with the internationally validated CKD Prognosis Consortium (CKD-PC) risk score for kidney disease progression (≥50% eGFR decline, end-stage kidney disease, or kidney-related death). We validated this approach using electronic health record data from UK primary care (Clinical Practice Research Datalink, 2013-2020) including adults with T2D, eGFR ≥60mL/min/1.73m^2, albuminuria <30mg/mmol, without atherosclerotic vascular disease or heart failure, starting either SGLT2-inhibitors or comparator drugs dipeptidyl peptidase-4 inhibitors/sulfonylureas (DPP4i/SU). We evaluated the real-world applicability of the relative treatment effect using overlap-weighted Cox proportional hazard models and assessed calibration of the CKD-PC risk score. We validated the accuracy of model-predicted benefit by comparing predicted and observed absolute risk reductions with SGLT2-inhibitors vs DPP4i/SU. We then compared clinical utility of a model-based treatment strategy to the ≥3mg/mmol albuminuria threshold.

Findings
In 53,096 initiations of SGLT2-inhibitor treatment compared with 88,404 initiations of DPP4i/SU, SGLT2-inhibitors were associated with a 43% relative risk reduction (HR 0.57 95% CI 0.48-0.68) in kidney disease progression, consistent with previous trial meta-analysis. The CKD-PC risk score did not require recalibration (calibration slope 1.05, 95% CI 0.94-1.17). Overall model-predicted benefit with SGLT2-inhibitors was median 0.37% at 3 years (IQR 0.26-0.55) and showed good calibration (calibration slope 1.04, 95% CI 0.91-1.17). Using model predictions to target the same proportion of the population as the albuminuria threshold would prevent over 10% more events over 3 years (253 vs 228), by identifying a subgroup of 6.7% of individuals with albuminuria <3mg/mmol with significantly greater benefit from SGLT2-inhibitor treatment than the rest with albuminuria <3mg/mmol (3.2% vs 1.2% in extended 5-year observational analyses, p=0.05).

Interpretation
A model based on adapting the international CKD-PC risk score can accurately identify which individuals with T2D have clinically relevant kidney protection benefit from SGLT2-inhibitors. This allows more effective targeting of SGLT2-inhibitor treatment than the ≥3mg/mmol albuminuria threshold recommended by current international guidelines and could be applied worldwide.

INTRODUCTION

SGLT2-inhibitors are now widely recommended for kidney protection
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are now widely recognised for their effect on lowering risk of kidney failure[1]. Consequently, international guidelines broadly recommend SGLT2-inhibitors to all individuals with type 2 diabetes (T2D) with an estimated glomerular filtration rate (eGFR) ≥20mL/min/1.73m^2 and chronic kidney disease (CKD), as defined by a reduced eGFR (<60mL/min/1.73m^2) or albuminuria (urinary albumin/creatinine ratio [uACR]) ≥3mg/mmol[2,3].

Guidelines extrapolate kidney protection benefit beyond kidney outcome trial evidence to include a large group based on low-level albuminuria only
However, these recommendations are extrapolations beyond evidence from SGLT2-inhibitor kidney outcome trials. Notably, these trials included individuals with markedly reduced eGFR (20-45mL/min/1.73m^2) or severe albuminuria (≥22.6mg/mmol) but did not include those with preserved eGFR (≥60mL/min/1.72m^2) and low-level albuminuria[4-6]. While data from cardiovascular outcome trials suggest that these individuals have similar *relative* risk reductions in adverse kidney outcomes from SGLT2-inhibitors compared to individuals studied in kidney outcome trials[7-9], it remains unclear whether they have clinically meaningful *absolute* risk reductions. Furthermore, this uncertainty applies to individuals with preserved eGFR and normal albuminuria (<3mg/mmol), whom current guidelines do not recommend treating with SGLT2-inhibitors.

The alternative to treatment strategy based on a fixed albuminuria threshold is individualised targeting based on $pARR$
A more precise alternative to the ≥3mg/mmol albuminuria threshold could be to target SGLT2-inhibitor treatment based on an individual's predicted absolute risk reduction ($pARR$). This could be feasible with existing clinical prediction models, such as the internationally validated CKD Prognosis Consortium (CKD-PC) risk score which predicts an individual's 3-year absolute risk of kidney disease progression[10] using routine clinical features. By integrating this risk score with the relative treatment effect of SGLT2-inhibitors derived from trial meta-analyses, an individual's likely absolute risk reduction with SGLT2-inhibitor treatment – i.e. potential benefit – could be estimated. This approach is widely used in cardiology and other fields (e.g. for individualised prescribing of statins for cardiovascular protection[11,12]) but has not yet been applied to T2D.

We aim to integrate trial data and prediction model to predict ARR in this population
We aimed to evaluate whether a risk score-based approach could accurately predict absolute risk reductions in kidney disease progression with SGLT2-inhibitors among individuals with T2D, preserved eGFR, and normal or low-level albuminuria, who were not studied in kidney outcome trials. To achieve this, we derived predicted absolute risk reductions ($pARR$) by integrating the relative treatment effect from SGLT2-inhibitor trial meta-analysis with the CKD-PC risk score in real-world primary care data. We then compared the clinical utility of treatment strategies based on $pARR$ to the currently recommended albuminuria threshold for SGLT2-inhibitor initiation.

METHODS

Data sources
We used UK routine clinical data from Clinical Practice Research Datalink (CPRD) Aurum. CPRD contains information recorded during routine general practice, including demographic characteristics, diagnoses and symptoms, prescriptions, laboratory tests, and physiological measurements, and is broadly population-representative[13]. CPRD data were linked to national hospital inpatient data (Hospital Episode Statistics), Office for National Statistics (ONS) death data and Index of Multiple Deprivation 2015 (IMD) data.

Study population
We included individuals with T2D initiating SGLT2-inhibitors as well as individuals not on SGLT2-inhibitors initiating dipeptidyl peptidase-4 (DPP4) inhibitors or sulfonylureas as comparator drugs (neither drug classes are not known to alter kidney disease progression[14,15]), between January 21st, 2013, and October 15th, 2020, with at least 3 months of registration data before first prescription. We defined the date of a first-ever prescription for an SGLT2-inhibitor or DPP4-inhibitor/sulfonylurea as treatment initiation and study baseline.

We excluded individuals as per the following criteria: a prior diagnosis of heart failure or atherosclerotic vascular disease (ischaemic heart disease or angina, peripheral vascular disease, revascularisation, stroke, or transient ischaemic attack) given the clear indication for SGLT2-inhibitors due to cardiovascular benefit[16]; missing baseline eGFR or uACR; eGFR <60mL/min/1.73m^2 or albuminuria ≥30mg/mmol; end-stage kidney disease (ESKD); and concurrent prescription for glucagon-like peptide-1 receptor agonists (GLP1-RA) due to their kidney protective effects[17]. To align with the population used for development of the CKD-PC clinical prediction model, we also excluded those with body mass index (BMI) <20kg/m^2, and age <20 years or >80 years[10]. For subgroup analyses, low-level albuminuria (3-30mg/mmol) was defined as having 2 consecutive uACR readings meeting this threshold.

Treatment
DPP4-inhibitors and sulfonylureas were considered a single comparator arm due to their similar risk profiles for kidney disease progression[14,15]. We confirmed the validity of this approach (see sensitivity analysis). All individuals were followed from drug initiation until the earliest of the outcome event, death, GP practice deregistration, the last date of the study period, the date of GLP1-RA initiation, or a maximum of three years (in additional analyses extended to five years). Individuals in the comparator arm starting an SGLT2-inhibitor during follow-up were censored at the date of SGLT2-inhibitor initiation. They were subsequently included in the SGLT2-inhibitor arm from the same date, allowing inclusion of two non-overlapping follow-up periods for these individuals. We did not censor individuals in either group who started treatment with DPP4-inhibitors or sulfonylureas during follow-up.

Outcomes
The primary outcome was kidney disease progression, defined as a composite of a sustained ≥50% decline in eGFR, ESKD (requirement for renal replacement therapy or sustained eGFR <15mL/min/1.73m^2), and death with any cause listed as kidney-related. This outcome was selected to align with the SGLT2-inhibitor trial individual participant data meta-analysis[1]. Secondary outcomes comprised a similar composite of a ≥40% decline in eGFR or ESKD, progression to albuminuria ≥30mg/mmol, diabetic ketoacidosis, amputation, and mycotic genital infections.

Risk score
We estimated 3-year absolute risk of kidney disease progression using the CKD-PC risk

score for ≥50% decline in eGFR. This risk score uses the same routine clinical features (age, sex, eGFR, uACR, systolic blood pressure, HbA1c, BMI, smoking status, use of antihypertensive medications, use of oral glucose-lowering treatments, use of insulin, previous diagnosis of atrial fibrillation, and previous diagnosis of heart failure or coronary heart disease) and is highly correlated (Pearson's R 0.94) with the online available risk score for ≥40% decline in eGFR or ESKD[10].

Covariates
Covariates included current age (years), sex (male/female), ethnicity (white, black, South Asian, mixed and other or unknown), index of multiple deprivation (IMD) quintile, BMI (kg/m^2), systolic blood pressure (mmHg), total cholesterol (mmol/L), HbA1c (mmol/mol), eGFR (using the Chronic Kidney Disease Epidemiology Collaboration formula, in mL/min/1.73m^2)[18], uACR (mg/mmol), duration of T2D (years), smoking status (non-smoker, ex-smoker, and current smoker), previous diagnosis of hypertension, atrial fibrillation, and hospitalisation in the year before baseline, calendar year at baseline, number of current glucose-lowering treatments (1, 2, and 3 or more), concurrent prescriptions for statins, insulin, and angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers (full covariate set). For physiological and laboratory measurements, the closest value to baseline in the previous 2 years was taken.

Statistical analyses
Baseline clinical features
Missing clinical data (index of multiple deprivation 0.1%, BMI 3.1% [i.e. either height or weight missing], blood pressure 0.2%, total cholesterol 0.3%, HbA1c 0.2%, diabetes duration 5.8%, smoking status 0.6%) were imputed 10 times using multivariate imputations with chained equations. IMD and smoking status were imputed with multinomial regression, BMI with passive imputation, and all other variables with predictive mean matching. We performed all analyses in each individual imputed dataset and pooled the results according to Rubin's rules[19].

Estimation of the relative effect of SGLT2-inhibitors on kidney disease progression
We estimated risk of kidney disease progression with SGLT2-inhibitors vs DPP4-inhibitors/sulfonylureas, overall and by presence of albuminuria. We estimated relative effects of SGLT2-inhibitors using doubly robust overlap-weighted Cox proportional hazards models[20,21]. As sensitivity analyses, we tested alternative methods, including doubly robust inverse probability of treatment weighted (IPTW) analyses (weights truncated at 2nd and 98th percentiles)[22], and multivariable adjustment (full covariate set). Weights were derived from a multivariable logistic regression-based propensity score model including the full covariate set. We also explored whether the continuous CKD-PC risk score modified the relative effect of SGLT2-inhibitors, with risk score fitted as a non-linear term (3-knot restricted cubic spline) interacting with treatment (adjusting for the full covariate set).

Derivation of predicted SGLT2-inhibitor 3-year absolute risk reductions
We first assessed calibration of the CKD-PC risk score[10] for predicting the primary outcome by visually comparing predicted and observed outcome proportions per risk score decile and fitting a Cox proportional hazards model with the linear predictor as the only variable, calculating a new baseline hazard (calibration-in-the-large) and calibration slope[23]. Overall fit was assessed using the Brier score, and discrimination using the C-statistic, with confidence intervals derived from 500 bootstrap samples

We then used the risk score to estimate individual-level predicted absolute risk reductions from SGLT2-inhibitors ($pARR$) at 3 years as follows: $pARR = S(0)t^{HR} - S(0)t$, where HR

represents the relative treatment effect from SGLT2-inhibitor trial meta-analysis (0.62)[1], and $S(0)t$ an individual's predicted kidney disease progression-free survival at 3 years.

Validation of SGLT2-inhibitor 3-year $pARR$
Direct validation of $pARR$ at the individual level was not possible, as counterfactual outcomes for each patient are unobservable, i.e. what would have happened had a patient received the alternative treatment. Building on our previous work validating models predicting differential glycaemic response to T2D medications[24], we assessed the calibration of $pARR$ using an approach tailored to time-to-event data. We used doubly robust overlap-weighted Cox proportional hazards models, incorporating treatment and covariates as previously described, to estimate 3-year observed counterfactual absolute risk reductions with SGLT2-inhibitors. We assessed calibration accuracy by visually comparing $pARR$ to observed counterfactual absolute risk reductions across deciles of $pARR$ and by estimating a calibration slope.

Comparison of treatment strategies based on $pARR$ to current guideline recommendations
We used decision curves to compare the clinical utility of two treatment strategies[25,26]: a strategy based on albuminuria ≥3mg/mmol (as recommended by current guidelines[2]) and a strategy based on $pARR$. We chose a $pARR$ threshold where a comparable proportion of the population would be treated as under the albuminuria threshold. For all treatment strategies, we modelled the number treated, kidney disease progression events avoided, and average absolute risk reduction over 3 years. We modelled these outcomes by applying the risk score to individuals not recommended treatment and adjusting the risk scores for those recommended treatment. These adjusted risk scores incorporated the relative treatment effect from SGLT2-inhibitor trial meta-analysis[1]. We further illustrated these comparisons in extended observational analyses with 5-year doubly robust overlap-weighted observed absolute risk reductions.

Secondary outcomes
For all secondary outcomes, we estimated relative effects of SGLT2-inhibitors vs DPP4-inhibitors/sulfonylureas overall and by albuminuria status using doubly robust overlap-weighted Cox proportional hazards models, as described above.

Sensitivity analysis
To check the validity of taking DPP4-inhibitors and sulfonylureas as a single comparator arm, we estimated relative effects on kidney disease progression for each pairwise comparison of SGLT2-inhibitors, DPP4-inhibitors, and sulfonylureas, using Cox proportional hazards models with the three analytical approaches described above. In these analyses, subjects were censored if initiating any of the other study drugs.

All analyses were conducted with R version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria). We followed TRIPOD prediction model reporting guidelines.

Role of the funding source

Ethics and data approvals
Approval for the study was granted by the CPRD Independent Scientific Advisory Committee (eRAP 22_002000) and Vivli (ID 00005959). CPRD obtains annual research ethics approval from the UK's Health Research Authority Research Ethics Committee (05/MRE04/87) to

receive and supply patient data for public health research; no further ethical permissions were required for the analyses of these anonymised patient-level data.

RESULTS

Study population

We included individuals with T2D who received a first-ever prescription for SGLT2-inhibitors (n=53,096) or DPP4-inhibitors/sulfonylureas (n=88,404), with preserved eGFR (≥60mL/min/1.73m^2) and normal or low-level albuminuria 0-30mg/mmol (Supplemental Figure 1). The mean age was 58 ±11 years; 83,976 (59%) were men; and none had a history of heart failure or atherosclerotic vascular disease. Baseline characteristics by treatment arm are reported in Table 1. In the SGLT2-inhibitor arm, 10,018 (19%) had low-level albuminuria (3-30mg/mmol), compared to 15,285 (17%) in the DPP4-inhibitor/sulfonylurea arm. Clinical characteristics by albuminuria status are reported in Supplemental Table 1.

Table 1. Baseline characteristics by treatment arm.

	SGLT2-inhibitors (n=53,096)	DPP4-inhibitors / sulfonylureas (n=88,404)
Sociodemographic characteristics		
Age, years (mean ±SD)	57 ±10	58 ±11
Male sex (n, %)	31,324 (59%)	52,652 (60%)
Ethnicity (n, %)		
White	39,579 (75%)	64,619 (73%)
South Asian	7,871 (15%)	13,269 (15%)
Black	2,803 (5%)	5,891 (7%)
Other	930 (2%)	1,601 (2%)
Mixed	585 (1%)	1,021 (1%)
Not stated/Unknown	1,328 (3%)	2,003 (2%)
Index of multiple deprivation, deciles (n, %)		
1-2	9,276 (17%)	14,519 (16%)
3-4	9,509 (18%)	15,781 (18%)
5-6	10,166 (19%)	16,813 (19%)
7-8	11,891 (22%)	20,012 (23%)
9-10	12,255 (23%)	21,279 (24%)
Laboratory and vital signs measurements		
BMI, kg/m^2 (mean ±SD)	33 ±7	32 ±7
Systolic blood pressure, mmHg (mean ±SD)	132 ±13	132 ±14
Diastolic blood pressure, mmHg (mean ±SD)	78 ±9	78 ±9
Total cholesterol, mmol/L (mean ±SD)	4.3 ±1.1	4.5 ±1.1
HDL, mmol/L (mean ±SD)	1.2 ±0.3	1.2 ±0.3
LDL, mmol/L (mean ±SD)	2.2 ±0.9	2.3 ±0.9
HbA1c, mmol/mol (mean ±SD)	77 ±17	75 ±19
eGFR, mL/min/1.73m^2 (mean ±SD)	97 ±14	95 ±14
uACR, mg/mmol (median, IQR)	1.2 [0.6, 2.5]	1.1 [0.6, 2.4]
Albuminuria status (n, %)		
Normal albuminuria (<3mg/mmol)	43,078 (81%)	73,119 (83%)
Low-level albuminuria (3-30mg/mmol)	10,018 (19%)	15,285 (17%)
Comorbidities		
Diabetes duration at treatment start, years (median, IQR)	8.3 [4.8, 12.7]	6.1 [3.1, 10.1]
Smoking status (n, %)		
Non-smoker	28,546 (54%)	46,346 (52%)

Ex-smoker	16,641 (31%)	27,425 (31%)
Current smoker	7,909 (15%)	14,633 (17%)
Hypertension (n, %)	27,933 (53%)	44,676 (51%)
Atrial fibrillation (n, %)	1,156 (2%)	2,166 (2%)
Previous diabetic keto-acidosis (n, %)	264 (0%)	354 (0%)
Previous mycotic genital infection (n, %)	6,814 (13%)	9,298 (11%)
Hospitalisation in previous year (n, %)	9,387 (18%)	17,365 (20%)
Medications		
Calendar year at baseline (n, %)		
2013	892 (2%)	15,771 (18%)
2014	3,955 (7%)	14,081 (16%)
2015	7,015 (13%)	13,323 (15%)
2016	6,920 (13%)	11,432 (13%)
2017	7,921 (15%)	10,648 (12%)
2018	9,351 (18%)	9,957 (11%)
2019	10,871 (20%)	8,617 (10%)
2020	6,171 (12%)	4,575 (5%)
Number of current glucose-lowering treatments (n, %)		
1	3,044 (6%)	11,007 (12%)
2	21,318 (40%)	59,483 (67%)
3+	28,734 (54%)	17,914 (21%)
On statin (n, %)	44,493 (84%)	71,012 (80%)
On insulin (n, %)	5,597 (11%)	2,233 (3%)
On ACE-inhibitor or ARB (n, %)	32,906 (62%)	49,775 (56%)

Abbreviations: SD standard deviation, IQR interquartile range, BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation), uACR urinary albumin-creatinine ratio, ACE angiotensin-converting enzyme, ARB angiotensin-II receptor blocker.

SGLT2-inhibitors are associated with a consistently lower relative risk of kidney disease progression similar to trial meta-analysis

The incidence of kidney disease progression (≥50% decline in eGFR, ESKD, or death due to kidney-related causes) was lower with SGLT2-inhibitor treatment vs the comparator arm (2.2 vs 3.8 per 1000 person-years), with an overall 43% lower relative risk (overlap-weighted HR 0.57, 95% CI 0.48-0.68). This reduction in relative risk was consistent by albuminuria status (p=0.99 for interaction, Figure 1A) and continuous CKD-PC risk score (p=0.71 for non-linear and p=0.50 for linear risk score by treatment interaction term, Figure 1B). Sensitivity analyses confirmed similar relative effects using IPTW or multivariable adjustment alone (Supplemental Figure 2) and when comparing SGLT2-inhibitors to either DPP4-inhibitors or sulfonylureas separately (Supplemental Figure 3). The lower relative risk with SGLT2-inhibitor treatment was similar to previous SGLT2-inhibitor trial meta-analysis on the same outcome (HR 0.62, 95% CI 0.56-0.68)[1], supporting the use of this estimate in predicting the real-world effect of SGLT2-inhibitor treatment.

Figure 1. *Hazard ratio of kidney disease progression (≥50% decline in eGFR, ESKD, or death due to kidney-related causes) with SGLT2-inhibitors by albuminuria status and CKD-PC risk score. Panel A shows a forest plot with overlap-weighted hazard ratios for kidney*

disease progression over 3 years with SGLT2-inhibitors compared to DPP4-inhibitors/sulfonylureas overall and by albuminuria status. Panel B shows the continuous association between risk score (CKD-PC risk score for 3-year risk of kidney disease progression) and multivariable-adjusted hazard ratio for 3-year risk of kidney disease progression with SGLT2-inhibitors compared to DPP4-inhibitors/sulfonylureas, modelled using restricted cubic splines with 3 knots. For comparison, the trial meta-analysis hazard is represented by ratio red dashed lines (0.62, 95% CI 0.56-0.68).

An existing risk score can predict risk of kidney disease progression with good accuracy

The CKD-PC risk score predicting absolute risk of kidney disease progression showed modest discrimination (C-statistic: 0.68, 95% CI 0.67-0.69). This was lower than the C-statistic reported in the original validation study (which included people with severe albuminuria; 0.78, 95% CI 0.77, 0.79) but higher than the C-statistic for continuous uACR (0.60, 95% CI 0.60-0.61). Overall prediction accuracy of the CKD-PC risk score was good (Brier score 0.0104, 95% CI 0.0097-0.0111). The risk score also showed good calibration (calibration-in-the-large: 0.990, 95% CI 0.989-0.991; calibration slope: 1.05, 95% CI 0.94-1.17; Supplemental Figure 4), meaning risk score recalibration was not required.

Integrating SGLT2-inhibitor relative risk estimates with the CKD-PC risk score can accurately predict absolute risk reductions

The predicted 3-year absolute risk reduction (   ) with SGLT2-inhibitors, estimated by integrating the relative treatment effect from SGLT2-inhibitor trial meta-analysis (HR 0.62) with the CKD-PC risk score, was median 0.37% (IQR 0.26-0.55) overall.   showed good calibration accuracy (Figure 2), with a calibration slope of 1.04 (95% CI 0.91-1.17).

Figure 2. *Calibration of predicted 3-year absolute risk reductions with SGLT2-inhibitor treatment ($pARR$) compared to observed counterfactual absolute risk reductions derived from doubly robust overlap-weighted Cox models (median and interquartile range shown), stratified by deciles of $pARR$.*

$pARR$ is generally higher in individuals with low-level albuminuria but there is variability across both groups

Figure 3 shows the distributions of $pARR$ in individuals with normal albuminuria <3mg/mmol (82.1% of the study population) and in individuals with low-level albuminuria 3-30mg/mmol (17.9% of the population). $pARR$ was higher in individuals with albuminuria 3-30mg/mmol (median 0.81%, IQR 0.60-1.10 vs 0.33%, IQR 0.24-0.44). However, there was substantial variability in $pARR$ within and overlap across both groups.

Figure 3. *Distribution of predicted 3-year absolute risk reductions with SGLT2-inhibitor treatment ($pARR$) in kidney disease progression (≥50% decline in eGFR, ESKD, or death due to kidney-related causes) in individuals with normal albuminuria <3mg/mmol (whom current guidelines do not recommend treating with SGLT2-inhibitors) and low-level albuminuria 3-30mg/mmol (whom current guidelines recommend treating with SGLT2-inhibitors). A vertical dashed line is shown at the ≥0.65% $pARR$ threshold where a comparable proportion of the overall population would be targeted (17.9%) as when using a ≥3mg/mmol albuminuria threshold.*

A treatment strategy based on $pARR$ outperforms the current strategy based on albuminuria

To compare treatment strategies based on $pARR$ and albuminuria, we chose a $pARR$ threshold of ≥0.65% to match the proportion of the population (17.9%) identified by the ≥3mg/mmol albuminuria threshold (Figure 3). Decision curve analysis demonstrated that a treatment strategy based on $pARR$ consistently outperformed the ≥3mg/mmol albuminuria threshold across all levels of risk tolerance and for any $pARR$ threshold (Supplemental Figure 5). At a kidney disease progression risk tolerance of 1.72% (corresponding to $pARR$ 0.65%), using a $pARR$ threshold resulted in an average of 74 more true positives (treated individuals who developed kidney disease progression) and 75 more true negatives (non-treated individuals who did not develop kidney disease progression) per 100,000 individuals, compared to the ≥3mg/mmol albuminuria threshold. In practice, a treatment strategy based on $pARR$ ≥0.65% would treat the same number of individuals but is projected to prevent over 10% more cases of kidney disease progression over 3 years, with 253 events prevented compared to 228 with a strategy based on albuminuria ≥3mg/mmol (Table 2). An individual's $pARR$ can be calculated using our web tool (in beta): https://thijsjansz.shinyapps.io/shinyapp.

Table 2. Estimated number of kidney disease progression events over 3 years with different SGLT2-inhibitor treatment strategies modelled on the study population. Event numbers were estimated using the CKD-PC risk score and the relative risk reduction estimate from SGLT2-inhibitor trial meta-analysis (HR 0.62).

Strategy	N (%) treated with SGLT2-inhibitor	N (%) with kidney disease progression over 3 years	N events avoided (% of total avoidable)	Average 3-year absolute risk reduction

Treat none	0 (0%)	1,727 (1.2%)	0 (0%)	-
Treat all	141,500 (100%)	1,075 (0.8%)	652 (100%)	0.46%
Albuminuria threshold ≥3mg/mmol	25,303 (17.9%)	1,499 (1.1%)	228 (35.0%)	0.90%
$pARR$ threshold ≥0.65%	25,303 (17.9%)	1,474 (1.0%)	253 (38.8%)	1.00%

Abbreviations: $pARR$ predicted absolute risk reduction with SGLT2-inhibitors.

The $pARR$ strategy identifies a high-benefit subgroup among individuals with normal albuminuria.

The treatment strategy based on $pARR$ ≥0.65% identified a high-benefit subgroup within individuals with albuminuria <3mg/mmol, comprising 6.7% of them. These individuals were more likely to be female (56 vs 40%) and have higher systolic blood pressure (mean 140 vs 131mmHg), HbA1c (mean 92 vs 73mmol/mol), and albuminuria (median 2.3 vs 0.8mg/mmol, Supplemental Table 2). Extended observational analyses confirmed that among individuals with albuminuria <3mg/mmol, those with 3-year $pARR$ ≥0.65% had significantly higher benefit over 5 years compared to those with 3-year $pARR$ <0.65% (observed 5-year absolute risk reduction 3.2% vs 1.2%, p=0.05, Figure 4). In contrast, among individuals with albuminuria 3-30mg/mmol, the 30.7% with 3-year $pARR$ <0.65% had a much lower 5-year observed absolute risk reduction of only 1.1%, compared to 2.4% in those with $pARR$ ≥0.65%.

Figure 4. *Bar chart showing the observed 5-year absolute risk reduction in kidney disease progression (≥50% decline in eGFR, ESKD, or death due to kidney-related causes) with SGLT2-inhibitors in subgroups of individuals by treatment recommendation based on albuminuria ≥3mg/mmol (striped vs solid) or predicted benefit ($pARR$; grey vs yellow). The ≥0.65% $pARR$ threshold was chosen to target a comparable proportion of the population to the ≥3mg/mmol albuminuria threshold. Observed absolute risk reductions were derived from doubly robust overlap-weighted Cox proportional hazards models. Error bars depict 95% confidence intervals.*

*p=0.05

No evidence of increased harm with treatment strategy based on
The relative effects of SGLT2-inhibitors on the secondary outcomes of 40% decline in eGFR/ESKD and progression to albuminuria ≥30mg/mmol were consistently seen in both subgroups defined by presence of low-level albuminuria (<3 and ≥3mg/mmol) and
        (Supplemental Figure 7A). Similarly, although the risk of both diabetic ketoacidosis and mycotic genital infection was higher with SGLT2-inhibitors (HR 1.92, 95% CI 1.51-2.44, and 3.03, 95% CI 2.85-3.03, respectively), with no evidence of a difference in risk for amputation, these associations did not differ by presence of low-level albuminuria or
        (Supplemental Figure 7B).

DISCUSSION

Our model can predict absolute risk reductions with SGLT2-inhibitors and guide treatment, which is superior to using an albuminuria threshold

Our model adapting the CKD-PC risk score can accurately predict kidney protection benefit with SGLT2-inhibitors among individuals with T2D, preserved eGFR, and normal or low-level albuminuria. Compared to the ≥3mg/mmol albuminuria threshold currently recommended in international guidelines, a model-based treatment strategy targeting the same number of individuals would prevent over 10% more kidney disease progression events and identifies a previously unrecognised subgroup with normal albuminuria that has significant kidney protection benefit. This novel approach leverages an internationally validated risk score and gold-standard evidence from large-scale trial meta-analysis, which could be applied across diverse settings worldwide providing a low-cost precision medicine tool that could be widely implemented.

No evidence of heterogeneity of treatment effects in robust analyses

Our study provides robust evidence of a consistent effect of SGLT2-inhibitors on the relative risk of kidney disease progression, with no indication of treatment effect heterogeneity. This aligns with prior analyses of randomised trials showing consistent effects by eGFR and albuminuria status[7-9]. Importantly, we tested for potential heterogeneity by continuous risk score, which indicated stable treatment effects across the spectrum of kidney disease progression risk. Together, these findings reinforce that SGLT2-inhibitors uniformly reduce the relative risk of kidney disease progression, irrespective of an individual's CKD stage or progression risk.

First study to evaluate absolute risk reductions in T2D with preserved eGFR and normal to low-level albuminuria

While the relative treatment effect of SGLT2-inhibitors is well-established, their absolute kidney protection benefit had not yet been evaluated in individuals with preserved eGFR and normal or low-level albuminuria. This group, which represents over 75% of individuals with T2D[27], was excluded from SGLT2-inhibitor kidney outcome trials[4-6]. Although they were included in cardiovascular outcome trials, these lacked analysis of absolute risk reductions by specific eGFR and albuminuria subgroups[7,8]. Our study reveals a wide range of absolute risk reductions in this population and presents a model to predict this at an individual level. Notably, this model identifies a previously unrecognised subgroup with normal albuminuria who have significant kidney protection benefit (3-year predicted absolute risk reduction [$pARR$] of 0.8%). For context, the 3-year absolute risk reduction derived from meta-analysis of kidney outcome trials (individuals with eGFR ≥20mL/min/1.73m^2 and albuminuria ≥22.6mg/mmol or eGFR 20-45mL/min/1.73m^2 and any albuminuria level) was 3.3%[1]. While further health economic analyses are needed to study the cost-effectiveness of different treatment thresholds based on $pARR$, our decision curve analysis demonstrates that a model-based treatment strategy outperforms the current albuminuria threshold at any threshold of $pARR$. Implementing such a strategy could thus improve kidney outcomes while also optimising resource utilisation.

Strengths

Our prediction model integrates high-level evidence from trial meta-analysis[1] with an internationally validated clinical prediction model[10]. It was validated using robust epidemiological methods, including overlap-weighting, in granular, high-quality population data. As these data are independent from those used to develop the prediction model, our analyses serve as external validation. It is therefore highly generalisable and could be immediately applied to clinical practice. Furthermore, the model only requires routine clinical

features (such as age, sex, eGFR, albuminuria, systolic blood pressure, and HbA1c), facilitating straightforward implementation (see web tool in beta: https://thijsjansz.shinyapps.io/shinyapp). This enables pragmatic, low-cost precision medicine, which could be especially valuable in low- or middle-income countries, such as in South Asia, where T2D prevalence is high but SGLT2-inhibitor prescribing is more resource-constrained[28]. While setting-specific optimisation might be required for use in other populations, the robust performance of the risk score in our cohort without requiring recalibration suggests that any necessary adjustments would likely only involve straightforward recalibration of baseline risks, ensuring local applicability without the need for modifications to the model itself.

Limitations

Our study has some limitations. First, the CKD-PC risk score on which $pARR$ is based showed modest discrimination. The difference with the original validation study is likely due to our cohort not including individuals with severe albuminuria. However, despite this, the $pARR$ model showed greater discrimination and clinical utility than the current standard of care (albuminuria threshold), highlighting the model's added value in practice[29]. Another limitation is that individuals over 80 years old were not included in the present analyses. Future research should evaluate potential benefit in this population while accounting for competing risks. Additionally, treatment allocation was non-random in this study, leaving room for potential unmeasured confounding. Finally, follow-up for our primary analysis was limited to 3 years due to the risk score's 3-year prediction window[10], and to align with most clinical trials[1], although we were able to show in observational analysis that treatment differences are maintained to 5-years. Longer-term studies are needed to explore lifetime benefit, which was beyond the scope of the present study.

Future work

Future work should aim to extend this study in several important areas. First, individuals with eGFR 45-60mL/min/1.73m^2 and normal or low-level albuminuria are also currently recommended SGLT2-inhibitor treatment for kidney protection but were not studied in kidney outcome trials[2,4-6]. We did not examine this group in our current analyses due to limited SGLT2-inhibitor use during the study period. Future studies are required to explore benefit prediction in this group. Second, our study focused on kidney outcomes, but SGLT2-inhibitors additionally provide cardiovascular and glycaemic benefits[1]. The ideal approach to integrating our result into clinical care, would come from developing a comprehensive framework for individual-level benefit prediction incorporating all relevant outcomes. Third, emerging treatments such as GLP1-RA have shown promise in reducing kidney disease progression risk[17], and future studies should assess which patients already treated with SGLT2-inhibitors might have most additional benefit from these drugs. Finally, integrating further predictors into our prediction model, such as genetic factors and novel biomarkers, could further improve precision and support more tailored treatment strategies, although at the expense of low-cost implementation.

Conclusion

In conclusion, our findings support using individual-level prediction of kidney protection benefit to target SGLT2-inhibitor treatment, providing a more precise and effective alternative to the albuminuria threshold currently recommended in international guidelines. By improving precision in treatment allocation, this approach has the potential to enhance kidney outcomes and optimise resource utilisation. As the prediction model only uses routine clinical features, it is straightforward to implement in clinical practice, offering a low-cost, globally applicable precision medicine tool that could be particularly valuable for resource-constrained settings where the burden of T2D is high.

ACKNOWLEDGMENTS

This article is based in part on data from the Clinical Practice Research Datalink (CPRD) obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. CPRD data is provided by patients and collected by the NHS as part of their care and support. This research was carried out at the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

FUNDING

This research was funded by the Medical Research Council (UK) (MR/N00633X/1) and supported by EFSD/Novo Nordisk.

DISCLOSURES

JMD is supported by a Wellcome Trust Early Career award (227070/Z/23/Z). ATH and BMS are supported by the NIHR Exeter Clinical Research Facility; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. AGJ declares research funding to his university from the UK Medical Research Council, NIHR, Diabetes UK, Breakthrough Type 1 diabetes, the Novo Nordisk Foundation and European Foundation for the Study of Diabetes. ERP has received honoraria for speaking from Lilly, Novo Nordisk and Illumina. RAO declares consulting income from Sanofi and honoraria from Sanofi and Novo Nordisk, in addition to research funding from NIDDK, Breakthrough T1D, The Leona M and Larry B Helmsley Charitable Trust, and Randox Ltd. No industry representatives were involved in the writing of the manuscript or analysis of data. For all authors these are outside the submitted work; there are no other relationships or activities that might bias, or be perceived to bias, their work.

DATA SHARING STATEMENT

CPRD data are available by application to the CPRD Independent Scientific Advisory Committee. All code lists and implementation algorithms are available at: https://github.com/Exeter-Diabetes/CPRD-Codelists/tree/pre-2024. Code to reproduce the analyses in this paper is available on https://github.com/Exeter-Diabetes/CPRD-Thijs-SGLT2-KF-scripts.

REFERENCES

1.	Nuffield Department of Population Health Renal Studies Group , SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet* 2022; **400**(10365): 1788-801.
2.	Kidney Disease: Improving Global Outcomes, Diabetes Work Group ,. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int* 2022; **102**(5S): S1-S127.
3.	Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2022; **45**(11): 2753-86.
4.	Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med* 2019; **380**(24): 2295-306.
5.	Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2020; **383**(15): 1436-46.
6.	Empa-Kidney Collaborative Group , Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2023; **388**(2): 117-27.
7.	Mosenzon O, Wiviott SD, Heerspink HJL, et al. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. *Diabetes Care* 2021; **44**(8): 1805-15.
8.	Cherney DZI, Charbonnel B, Cosentino F, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. *Diabetologia* 2021; **64**(6): 1256-67.
9.	Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. *Circulation* 2021; **143**(4): 310-21.
10.	Grams ME, Brunskill NJ, Ballew SH, et al. Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes. *Diabetes Care* 2022; **45**(9): 2055-63.
11.	Thanassoulis G, Williams K, Altobelli KK, Pencina MJ, Cannon CP, Sniderman AD. Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. *Circulation* 2016; **133**(16): 1574-81.
12.	Xu Z, Arnold M, Stevens D, et al. Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment. *Am J Epidemiol* 2021; **190**(10): 2000-14.
13.	Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *Int J Epidemiol* 2019; **48**(6): 1740-g.
14.	Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *JAMA* 2019; **321**(1): 69-79.
15.	Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. *JAMA* 2019; **322**(12): 1155-66.
16.	Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 2019; **393**(10166): 31-9.
17.	Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med* 2024; **391**(2): 109-21.
18.	Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. *N Engl J Med* 2021; **385**(19): 1737-49.
19.	Rubin DB, Schenker N. Multiple Imputation for Interval Estimation From Simple Random Samples With Ignorable Nonresponse. *Journal of the American Statistical Association* 1986; **81**(394): 366-74.
20.	Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of

major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. *Lancet Diabetes Endocrinol* 2023; **11**(9): 644-56.

21. Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. *JAMA* 2020; **323**(23): 2417-8.

22. Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. *Clin Kidney J* 2022; **15**(1): 14-20.

23. Steyerberg E. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating; 2009.

24. Dennis JM, Young KG, McGovern AP, et al. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. *Lancet Digit Health* 2022; **4**(12): e873-e83.

25. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. *Diagn Progn Res* 2019; **3**: 18.

26. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006; **26**(6): 565-74.

27. Cook S, Schmedt N, Broughton J, Kalra PA, Tomlinson LA, Quint JK. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink. *BMJ Open* 2023; **13**(3): e065927.

28. Gomes MB, Rathmann W, Charbonnel B, et al. Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. *Diabetes Res Clin Pract* 2019; **151**: 20-32.

29. Holmberg L, Vickers A. Evaluation of prediction models for decision-making: beyond calibration and discrimination. *PLoS Med* 2013; **10**(7): e1001491.